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ABSTRACT
The Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidelines for
ancillary therapy and supportive care in chronic graft-versus-host disease (GVHD), including treatment for
symptoms and recommendations for patient education, preventive measures, and appropriate follow-up; (2) to
provide guidelines for the prevention and management of infections and other common complications of
treatment for chronic GVHD; and (3) to highlight the areas with the greatest need for clinical research. The
definition of “ancillary therapy and supportive care” embraces the most frequent immunosuppressive or
anti-inflammatory interventions used with topical intent and any other interventions directed at organ-specific
control of symptoms or complications resulting fromGVHD and its therapy. Also included in the definition are
educational, preventive, and psychosocial interventions with this same objective. Recommendations are orga-
nized according to the strength and quality of evidence supporting them and cover the most commonly
involved organs, including the skin, mouth, female genital tract, eyes, gastrointestinal tract, and lungs.
Recommendations are provided for prevention of infections, osteoporosis, and steroid myopathy and manage-
ment of neurocognitive and psychosocial adverse effects related to chronic GVHD. Optimal care of patients
with chronic GVHD often requires a multidisciplinary approach.
© 2006 American Society for Blood and Marrow Transplantation
he opinions expressed here are those of the authors and do not represent the ofﬁcial position of the National Institutes of Health, Food and Drug
dministration, or the United States Government.
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TNTRODUCTION
Chronic graft-versus-host disease (GVHD) is
haracterized by polymorphic clinical manifestations
ith varying severity and clinical course. Prolonged
ystemic immunosuppressive treatment including cor-
icosteroids is necessary to control disease severity and
ecrease nonrelapse mortality. Treatment, combined
ith the delayed immunologic reconstitution associ-
ted with chronic GVHD, increases the risk of infec-
ions and other complications. Clinical manifestations
f chronic GVHD can persist for prolonged periods,
ausing signiﬁcant morbidity, and some may be irre-
ersible. Thus, ancillary therapy and supportive care
ecome central components in the long-term manage-
ent of chronic GVHD after allogeneic hematopoi-
tic cell transplantation (HCT).
URPOSE OF THIS DOCUMENT
The Ancillary Therapy and Supportive Care Work-
ng Group had 3 goals: (1) to establish guidelines for
ncillary therapy and supportive care in chronic
VHD, including treatment for symptoms and rec-
mmendations for patient education, preventive mea-
ures, and appropriate follow-up; (2) to provide guide-
ines for the prevention and management of infections
nd other common complications; and (3) to highlight
he areas in supportive care with the greatest need for
linical research.
In this document, the term “ancillary therapy and
upportive care” embraces the most frequent immuno-
uppressive or anti-inﬂammatory interventions with top-
cal intent and any other intervention directed at organ-
peciﬁc control of symptoms or complications resulting
rom GVHD and its therapy. Also included in this
eﬁnition are educational, preventive, and psychoso-
ial interventions with this same objective. Several
mportant aspects of diagnosis and good follow-up
are, such as monitoring for and management of med-
cation toxicities (hypertension, hyperlipidemia, renal
ysfunction, seizures, etc) and problems not directly
elated to chronic GVHD (eg, iron overload, psycho-
ocial adaptation) could not be included in this review.
nterested readers are referred to other publications
1-3].
The committee’s recommendations are organized
ccording to an evidence-based system to reﬂect the
trength of recommendations and the quality of evi-
ence supporting them (Appendix). It is hoped that
hese recommendations will serve as a platform for
ecognizing areas in need of cooperative clinical re-
earch projects. A version of this document posted on e
76he Internet (www.asbmt.org/GvHDForms) includes
dditional speciﬁc dispensary information.
The Working Group wishes to emphasize that the
ecommendations in this document represent a wide
ariety of generally accepted current medical prac-
ices. Good clinical judgment and individual circum-
tances should determine appropriate interventions
or speciﬁc patients.
UMMARY OF RECOMMENDATIONS
Table 1 provides a summary of ancillary therapy
nd supportive care interventions that is categorized
y organ system. Table 2 provides a summary of general
onitoring recommended for patients who are diag-
osed with chronic GVHD.
KIN AND APPENDAGES
See Table 3. Ancillary and supportive care of the
kin and appendages focuses on prevention, manage-
ent of manifestations such as pruritus, rash, pain,
yspigmentation, and limited range of motion and
opical care for erosions, ulcerations, and superinfec-
ion. Topical therapy plays an important role in alle-
iating symptoms and treating complications caused
y loss of skin integrity and immunosuppression. In
he absence of poor prognostic factors such as throm-
ocytopenia (100 000/L), treatment with cortico-
teroids at the time of diagnosis of chronic GVHD,
utaneous involvement of50% of total body surface,
nd a moderate or severe overall global score, topical
gents can serve as the primary treatment for cutane-
us chronic GVHD. Because skin cancer incidence is
ncreased in patients with chronic GVHD, biopsy
hould be obtained whenever clinically indicated.
easures to Prevent the Development or
xacerbation of GVHD
UV radiation can cause exacerbation of cutaneous
VHD [4]. Photoprotection includes protective cloth-
ng, sun avoidance, physical sunblocks, and sunscreens.
opically applied agents should protect against UV-A
nd UV-B. Micronized zinc, micronized titanium di-
xide, Mexoryl SX, or Parsol 1789 (avobenzone) are
seful additives to ensure adequate UV-A protection.
inse-cycle additives can enhance the barrier function
f clothing.
opical Care and Therapies: Intact Skin
Regular lubrication of dry but intact skin with
mollients may decrease pruritus and maintain skin
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Bable 1. Summary of Ancillary Therapy and Supportive Care Interventions
Organ System Organ-Specific Intervention*
kin and
appendages
Prevention
Photoprotection. Surveillance for malignancy.
Treatment
For intact skin — Topical emollients, corticosteroids, antipruritic agents, and others (eg, psoralen–UV-A,
calcineurin inhibitors).
For erosions/ulcerations — Microbiologic cultures, topical antimicrobials, protective films or other dressings,
debridement, hyperbaric oxygen, wound care specialist consultation.
outh and oral
cavity
Prevention
Maintain good oral/dental hygiene. Consider routine dental cleaning and endocarditis prophylaxis.
Surveillance for infection and malignancy.
Treatment
Topical high and ultra-high potency corticosteroids and analgesics. Therapy for oral dryness.
yes Prevention
Photoprotection. Surveillance for infection, cataract formation, and increased intraocular pressure.
Treatment
Artificial tears, ocular ointments, topical corticosteroids or cyclosporine, punctal occlusion, humidified
environment, occlusive eye wear, moisture chamber eyeglasses, cevimeline, pilocarpine, tarsorraphy,
gas-permeable scleral contact lens, autologous serum, microbiologic cultures, topical antimicrobials,
doxycycline.
ulva and vagina Prevention
Surveillance for estrogen deficiency, infection (herpes simplex virus, human papilloma virus, yeast, bacteria),
malignancy.
Treatment
Water-based lubricants, topical estrogens, topical corticosteroids or calcineurin inhibitors, dilators, surgery
for extensive synechiae/obliteration, early gynecologic consultation.
astrointestinal
tract and liver
Prevention
Surveillance for infection (viral, fungal).
Treatment
Eliminate other potential etiologies. Dietary modification, enzyme supplementation for malabsorption,
gastroesophageal reflux management, esophageal dilatation, ursodeoxycholic acid.
ungs Prevention
Surveillance for infection (Pneumocystis carinii, viral, fungal, bacterial).
Treatment
Eliminate other potential etiologies (eg, infection, gastroesophageal reflux). Inhaled corticosteroids,
bronchodilators, supplementary oxygen, pulmonary rehabilitation. Consideration of lung transplantation
in appropriate candidates.
ematopoietic Prevention
Surveillance for infection (cytomegalovirus, parvovirus).
Treatment
Eliminate other potential etiologies (eg, drug toxicity, infection). Hematopoietic growth factors,
immunoglobulin for immune cytopenias.
eurologic Prevention
Calcineurin drug-level monitoring. Seizure prophylaxis including blood pressure control, electrolyte
replacement, anticonvulsants.
Treatment
Occupational and physical therapies, treatment of neuropathic syndromes with tricyclic antidepressants,
selective serotonin reuptake inhibitors, or anticonvulsants.
mmunologic and
infectious diseases
Prevention
Immunizations and prophylaxis against Pneumocystis carinii, varicella zoster virus, and encapsulated bacteria
based on guideline of the Centers for Disease Control. Consider immunoglobulin replacement based on
levels and recurrent infections. No current evidence supports the use of mold-active agents. Surveillance
for infection (viral, bacterial, fungal, atypical).
Treatment
Organism-specific antimicrobial agents. Empiric parenteral broad-spectrum antibacterial coverage for fever.
usculoskeletal Prevention
Surveillance for decreased range of motion, bone densitometry, calcium levels and 25-OH vitamin D.
Physical therapy, calcium, vitamin D, bisphosphonates.
Treatment
Physical therapy, bisphosphonates for osteopenia and osteoporosis.
In general, close serial monitoring of all organ systems is recommended to promote early detection and intervention directed toward reversing
or preventing progression of chronic GVHD manifestations and treatment-associated toxicities. Ancillary and supportive care therapies are
commonly employed in addition to systemic GVHD treatment, although in some cases their use may circumvent the need for systemic
treatment or allow doses of systemic agents to be decreased.
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3ntegrity. Ointments and creams are better emollients
han are lotions, and these agents are less likely to
ting when applied to erythematous skin.
Nonsclerotic skin lesions without erosions or ulcer-
tions (lichen planus-like or papulosquamous plaques)
ay respond well to topical steroids and emollients.
ong-term use of topical steroids may be complicated
y local skin atrophy and development of striae.
. General guidelines regarding topical steroid rec-
ommendations for skin GVHD.
a. From the neck down: Treatment should begin
with mid-strength topical steroids (eg, triamcin-
able 2. Summary of Monitoring Recommendations*
nterval history with symptom assessment (including psychosocial
symptoms) and medication review (every 1-12 mo)
hysical examination (every 1-12 mo)
Weight (every 1-6 mo)
Height (adults: every 12 mo; children and adolescents: every
3-12 mo)
Nutritional assessment (every 1-12 mo)
Tanner score (children and adolescents: every 6-12 mo)
Developmental assessment (children and adolescents: every
3-12 mo)
aboratory monitoring
Complete blood cell counts with differential (every 1-6 mo)
Chemistry panel including renal and liver function tests
(every 1-6 mo)
Therapeutic drug monitoring (every 1-6 mo)
IgG level (every 1-6 mo until normal independent of
replacement)
Lipid profile (every 6-12 mo during treatment with
corticosteroids or sirolimus)
Iron indices (every 6-12 mo if red blood cell transfusions are
required or if iron overload has been documented
previously)
Pulmonary function tests (every 3-12 mo)
Endocrine function evaluation, eg, thyroid function tests, bone
densitometry, calcium levels, 25-OH vitamin D (every 12 mo)
ubspecialty evaluations
Ophthalmology with Schirmer test and glaucoma assessment
(every 3-12 mo)
Dental or oral medicine with comprehensive soft and hard
tissue examination, culture, biopsy or photographs of
lesions (as clinically indicated), and radiographs (every
6-12 mo)
Dermatology with assessment of extent and type of skin
involvement, biopsy, or photographs (as clinically indicated)
Gynecology for vulvar or vaginal involvement (as clinically
indicated)
Physiotherapy with assessment of range of motion (every
3-12 mo if sclerotic features are present)
Neuropsychological testing (every 12 mo as clinically
indicated)
All organ systems potentially affected by chronic GVHD or its
treatment [3] should be monitored serially in individuals at risk
at least annually for 5 years after HCT. The scope and fre-
quency of monitoring should be individualized as clinically in-
dicated. More frequent monitoring is strongly advised for those
with active GVHD, especially during high-risk periods (eg,
treatment taper or escalation), and for those who are participat-
ing in clinical trials.olone .1% cream or ointment). In unresponsive
78cases, short-term occlusion of mid-strength ste-
roids with damp towels (“wet wraps”) increases
skin hydration and steroid penetration. When
this is impractical, higher potency steroids (eg,
ﬂuocinonide .05% cream or ointment) may be
helpful. The most potent topical steroids (eg,
clobetasol dipropionate .05%, halobetasol pro-
pionate .05%) should not be used under occlu-
sion. The use of wet wraps and high potency
steroids should be limited to 14 consecutive
days, if possible.
b. Face, axillae and groin: Lower potency steroids
(hydrocortisone 1-2.5%, desonide .05%) are
preferable for long-term use.
c. Emollients: These may be used after the appli-
cation of steroids. Emollients are occlusive and
able 3. Ancillary Therapy and Supportive Care Recommendations
or Skin and Appendage GVHD*
Type of Intervention
Recommendation
Rating
reventive measures
Photoprotection: UV-A and UV-B
blockade including
Avoidance of sun exposure (especially
between 10:00 AM and 4:00 PM) AIII
Use of sunscreens (SPF >20 with
broad-spectrum UV-A and UV-B
protection) AIII
Protective clothing AIII
reatment
Intact Skin
Symptomatic treatment with
emollients and anti-pruritic agents AIII
Topical corticosteroids CIIb
Light therapy (PUVA, UV-A1, UV-B,
narrow band UV-B) CIIa
Topical calcineurin inhibitors
(pimecrolimus, tacrolimus) CIIa
Sclerotic manifestations with joint
stiffness or contractures
Deep muscle/fascial massage (Heller
works) to improve ROM CIII
Stretching exercises to improve ROM BIII
Erosions and ulcerations
Topical or oral antimicrobials BIII
Wound dressings and debridement CIII
Control of edema BIII
ediatric considerations
Systemic side effects of topical steroids may occur more
frequently in children because of the larger skin surface
area-to-body weight ratio
Although the least potent topical steroids (1-2.5%
hydrocortisone) are safe, middle to upper mid-strength
topical steroids should generally be used sparingly, and
on limited areas, for <3-4 wk
Topical steroids under occlusive dressings are not
recommended
The use of potent or superpotent steroids on the face or at
any site in infants <1 y of age is not recommended
SPF indicates sun protection factor; PUVA, psoralen–UV-A;
ROM, range of motion.may increase the potency of steroids.
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B. Antipruritics: Although pruritus related to GVHD
generally responds to immunosuppressive therapy,
other adjuvant treatments may be useful.
a. Topical: Hydrocortisone/pramoxine or men-
thol-based creams/lotions.
b. Systemic: Antihistamines (eg, diphenhydramine,
hydroxyzine, ranitidine) or the tricyclic agent
doxepin can be given.
. Others interventions.
a. Psoralen with UV-A [5-7], UV-A1 (340-400 nm)
[8], UV-B [9], or narrowband UV-B (311-313
nm) [10] can be effective, especially if sclerosis is
not present. Phototherapy may be administered
2-3 times per week by dermatologists.
Cautionary note: Phototherapy is associated
with an increased risk of skin cancer. A history
of skin cancer, aphakia, or photosensitivity may
be a contraindication to phototherapy.
b. Topical calcineurin inhibitors (eg, tacrolimus,
pimecrolimus) have been reported to improve
erythema and pruritus [11,12].
c. Topical bleaching agents (hydroquinone 4.0%
cream) alone or in combination with topical
tretinoin and steroids have been used to treat
postinﬂammatory hyperpigmentation in the set-
ting of inactive disease. The efﬁcacy of this in-
tervention is modest and depends on skin type
and depth of pigmentation.
opical Care for Nonintact Skin
When appropriate, superﬁcial or deep tissue cul-
ure should be obtained to test for bacterial, viral,
ungal, or mycobacterial infection in eroded, ulcer-
ted, or suspicious skin lesions. The differential diag-
osis for noninfectious skin lesions includes vasculitis,
ecurrent malignancy, GVHD, hypersensitivity or
rug reactions, dermatitis, and primary skin cancer.
In denuded skin, wound dressings maintain a
oist environment that enhances repair of the epithe-
ium, lysis of necrotic tissue, and phagocytosis of ne-
rotic debris. Protective ﬁlms may be applied to pre-
ent breakdown of fragile or compromised but
onulcerated skin. If indicated, topical antimicrobials
uch as mupirocin ointment or silver-containing prod-
cts may be useful.
Recalcitrant wounds or major wounds are best
reated in consultation with a plastic surgeon. Wounds
hat have been slow to heal may be treated with hy-
luronic acid products, collagen products, or ﬁbro-
last and keratinocyte products. Nonhealing wounds
hat involve the dermis may beneﬁt from platelet-
erived growth factor products. Hyperbaric oxygen
herapy has been used to treat hypoxic wounds [13].
Compression therapy may be indicated to facili-
ate drainage of periwound edema. The use of diuret-
cs can provide local beneﬁt in some instances, but v
B & M These beneﬁts must be weighed against the risk of
dverse effects on renal function in patients who re-
eive concomitant treatment with nephrotoxic immu-
osuppressive medications.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
OUTH AND ORAL CAVITY
See Table 4. Chronic GVHD involving the mouth
nd oral mucosa has 3 components: mucosal involve-
ent, salivary gland involvement, and sclerotic in-
able 4. Ancillary Therapy and Supportive Care Recommendations
or Mouth and Oral Cavity GVHD
Target Tissue Rating
ild/moderate* mucosal disease
Localized application of high potency topical
corticosteroids (fluocinonide gel 0.05%) AIIa
Generalized application of upper mid-strength
topical corticosteroids (dexamethasone
0.5 mg/5 mL, prednisolone 15 mg/5 mL,
triamcinolone 0.1%) AIIa
Topical analgesics (viscous lidocaine, 2%,
Kaopectate-Benadryl-Lidocaine oral rinse,
1:1:1, diclonine hydrochloride 1%) AIII
Localized application of upper mid-strength topical
corticosteroids (clobetasol gel 0.05% or
betamethasone dipropionate gel 0.05%) AIIb
Topical application of tacrolimus 0.1% ointment BIIa
Intralesional therapy with high-potency steroids for
refractory lesions (Kenalog 40, 0.3-0.4 mL for
1.0-cm2 lesion) BIII
Topical application of cyclosporine rinses (requires
compounding by pharmacist) CIIa/Ib
Oral phototherapy (psoralen–UV-A, UV-B, or
narrow band UV-B but none is widely available) CIIa
Topical application of azathioprine rinses (requires
compounding by pharmacist) CIII
alivary gland disease
Home fluoride therapy (neutral sodium fluoride) AIb
Frequent water sipping and saliva substitutes AIII
Salivary stimulants (sugar-free gum, sugar-free
candy) AIII
Mild dentrifice use AIII
Sialogogues
Cevimeline BIb
Pilocarpine BIb/IIa
clerotic perioral and intraoral diseases
Intralesional corticosteroid therapy CIII
ediatric considerations
Oral manifestations in children generally respond well to
dexamethasone rinses
Prolonged use of ultrahigh potency steroids should be avoided
in the very young child because of the potential for greater
systemic effects
There is limited experience, and dosing is not established for
the use of sialogogue therapy in children
Specific approaches to help parents assist children with
topical oral therapies may improve pediatric compliance
Deﬁnitions of severity are provided in the diagnosis and scoring
document [3].olvement of the mouth and surrounding tissues. Oral
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3hronic GVHD can cause pain, odynophagia, taste
mpairment, dryness, and decreased range of motion.
nfection with herpes simplex virus (HSV), human
apilloma virus, Candida, and other fungal organisms
hould be ruled out before initiating any form of
herapy. When clinically indicated, viral and bacterial
ultures and biopsies should be performed.
Patients with persistent or new oral lesions that
ccur 3 years after HCT should be evaluated for
econdary cancer involving the oral cavity (especially
quamous cell carcinoma). These cancers generally
egin as leukoplakia, which may be misdiagnosed as
hronic GVHD. Leukoplakia must be biopsied peri-
dically to rule out progression to frank malignancy.
hen leukoplakia is caused by chronic GVHD, ag-
ressive treatment with clobetasol usually results in
esolution or considerable softening of the “white le-
ion” but persistence or worsening of the lesion re-
uires biopsy. Suspicious lesions of the vermillion
order of the lip also require biopsy and culture.
Ancillary treatment may provide greater local ben-
ﬁts than systemic therapy alone. When the oral cav-
ty is the only site of chronic GVHD activity, with
ild to moderate severity, ancillary treatment might
ufﬁce to control the disease in the absence of systemic
herapy. However, systemic therapy should be added
arly in the treatment of severe oral cavity GVHD (eg,
kin sclerosis) and whenever isolated oral cavity
VHD fails to respond to ancillary measures.
ral Cavity and Vermillion Border Chronic GVHD
The mainstay of therapy for localized and symp-
omatic disease is the application of a high potency
orticosteroid gel (ﬂuocinonide, clobetasol, or beta-
ethasone dipropionate) [14-16]. It is also appropri-
te to treat asymptomatic pseudomembranous ulcers
o reestablish integrity of the mucosal barrier. The
pplication of tacrolimus ointment is an alternative to
ocally applied corticosteroids [17,18]. Vaseline-based
intments such as topical tacrolimus are generally less
ffective in the mouth than are alcohol-based cortico-
teroid gels but are preferable for the treatment of
chapped lips” caused by GVHD, because high po-
ency steroids cause irreversible atrophy when applied
o the vermillion border of the lips. Discrete lesions
hat fail to respond to topical therapy may resolve
ithin 3-4 weeks after weekly intralesional injections
f triamcinolone [14].
The mainstay of therapy for more generalized and
ymptomatic disease is corticosteroid rinses directed
t the entire oral cavity. Dexamethasone and other
orticosteroid rinse formulations such as prednisolone
r triamcinolone are held and swished in the mouth
or 4-6 minutes and then expelled without swallowing.
reatments are administered 4-6 times per day14,16]. Alternative noncorticosteroid rinse formula- r
80ions of cyclosporine or azathioprine may be effective
n refractory cases [19]. Systemic treatment with aza-
hioprine has been associated with an increased risk of
econdary malignancy. For this reason, patient should
e counseled about the risk of oral cancer, and the
uration of treatment with azathioprine rinses should
enerally not exceed 12 months. Associations between
ther topical immunosuppressants and secondary can-
ers have been less well studied.
All patients should be counseled about the rela-
ively frequent side effect of oral candidiasis, which
an be managed with appropriate prophylaxis or treat-
ent. Patients should also be warned about systemic
ffects that can result from topical therapy with highly
otent steroids.
Topical analgesia is helpful when symptomatic
ucosal GVHD impairs nutrition or communication.
iscous lidocaine is often effective.
alivary Gland Chronic GVHD
Patients with salivary gland involvement most fre-
uently report dry mouth and variable oral sensitivi-
ies to hot, cold, spicy, and acidic food, mint (such as
oothpaste), and carbonated beverages [14,20,21].
hey may also develop mucoceles, which are recog-
ized as painless blisters on the palate and inside the
ower lip [22,23].
Ancillary care for dry mouth may include frequent
ater sipping, the use of salivary stimulants (sugar-
ree gum and candy), oral moisturizing agents, and
aliva substitutes. Symptomatic patients should avoid
int-ﬂavored dentifrices and whitening products.
he milder ﬂavored dentifrices marketed for children
re often tolerated. Caries can be prevented by home
uoride treatments before sleep. Even in patients
ithout subjective oral dryness, mild salivary gland
ysfunction can increase the risk of tooth decay, and
opical ﬂuorides should be offered as a decay-preven-
ion strategy [14,24]. If possible, avoidance of xerogenic
edications such as tricyclic antidepressants, speciﬁc se-
otonin reuptake inhibitors, antihistamines, and narcotic
nalgesia can substantially alleviate symptoms of dry
outh. Sialogogue therapy with cholinergic agonists
cevimeline, pilocarpine) may produce a signiﬁcant en-
ancement of salivary secretion and may be offered in
he absence of contraindications (eg, glaucoma, heart
isease, or asthma) [25,26].
Superﬁcial mucoceles require no treatment.
ymptomatic mucoceles should be distinguished from
erpetic lesions and may respond to topical steroids or
opical analgesics. Deep mucoceles require surgical
xcision, particularly when they cause symptoms.
clerotic Manifestations of Chronic GVHD
Topical therapy alone is insufﬁcient to treat scle-
osis of the perioral skin and surrounding tissues
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Baused by chronic GVHD. In this situation, systemic
reatment is required. Adjunctive intralesional steroid
njections may be helpful, but long-term therapy is
ften required to maintain the response. Stretching
xercises to increase range of motion of the mouth
ay be helpful.
outine Dental Treatment
No consensus could be reached regarding the ad-
isability of routine dental cleanings or the need for
ndocarditis prophylaxis in patients with chronic
VHD. When dental treatment is required, the
merican Heart Association’s guidelines for preven-
ion of bacterial endocarditis provide recommenda-
ions with regard to antibiotic prophylaxis, but no
ecommendations for patients with chronic GVHD
ave been published, and the need for routine pro-
hylaxis in patients with chronic GVHD is controver-
ial [27]. These guidelines may be appropriate for
atients with delayed immune reconstitution, persis-
ently low counts (especially absolute neutrophil
ount), or a history of infectious complications after
CT. Extended antibiotic therapy based on the den-
al disease, the type of treatment, and the patient’s
isk for infection should be determined by the treat-
ng dental physician or oral surgeon in consultation
able 5. Ancillary Therapy and Supportive Care Recommendations for
Therapy
opical Mild*
Artificial Tears, preservat
Viscous ointment at bedti
Moderate/severe*
Cyclosporine eye drops
Topical steroid drops
Lacriserts for patients wh
ral Moderate/severe*
Cevimeline
Pilocarpine
Doxycycline
urgical Moderate/severe*
Punctal occlusion (tempo
cautery)
Superficial debridement o
Partial tarsorrhaphy
yewear/environmental strategy Moderate/severe*
Occlusive eye wear (www
Lid care/warm compress/h
Bandage contact lens (use
reatment not widely available Moderate/severe*
Autologous serum eye dr
Gas-permeable contact le
ediatric considerations
Although severe ocular sicca is uncommon in children with chr
for keratoconjunctivitis sicca is necessary
Ocular sicca generally responds to ancillary measures in conjun
Experience is limited, and dosing is not established for many o
Deﬁnitions of severity follow the diagnosis and scoring report [3]ith the transplantation center. d
B & M TFor speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
YES
See Table 5. The clinical spectrum of chronic ocular
VHD includes acute conjunctival inﬂammation,
seudomembranous and cicatricial conjunctivitides, and
eratoconjunctivitis sicca (KCS) syndrome. This report
ill focus on the dry eye syndrome (KCS). KCS often
ccompanies chronic GVHD activity in other organs
nd may be a prominent disease manifestation; con-
ersely, dry eyes may occasionally be the only mani-
estation of chronic GVHD [28]. The diagnosis of
CS is made by the presence of appropriate symp-
oms, tear production averaging 5 mm (Schirmer
est), and clinical signs of keratitis. Although ocular
ymptoms and external examination can be ascer-
ained from a clinic visit, a slit lamp examination by an
phthalmologist is generally required to make the
iagnosis of KCS. In all cases, infectious keratitis must
e ruled out. Most symptomatic treatments for ocular
hronic GVHD are aimed at relief of dry eyes.
Symptoms include burning, irritation, pain, for-
ign body sensation, blurred vision, photophobia, and,
aradoxically, excessive tearing [29]. Other causes of
HD
Indication Rating
AIb
cous tears during the day BIb
CIb
BIIIa
rtificial Tears more frequently than hourly CIb
CIb
CIb
CIII
permanent occlusion, using silicone plugs or thermal BIb
entary keratitis CIII
CIIb
pain.com; www.panoptx.com) BIII
fied environment CIII
extreme caution)
CIb
ston scleral lens prosthesis, www.bostonsight.org) CIIa
VHD, measured tear production is decreased, and surveillance
ith systemic immunosuppression
pical and oral medications for ocular GVHDEye GV
ive free
me, vis
o use A
rary or
f filam
.dryeye
umidi
d with
ops
ns (Bo
onic G
ction w
f the tory eyes need to be considered, such as medications
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3ith anticholinergic side effects (antihypertensives,
ntidepressants, psychotropics, antihistamines, decon-
estants) and previous treatments (eg, total body irra-
iation, chemotherapy, history of autologous HCT).
Aqueous tear deﬁciency/lacrimal gland dysfunc-
ion may ﬂuctuate during systemic GVHD. Although
ystemic immunosuppressive therapies for chronic
VHD generally do not lead to improvement in
chirmer scores (especially if lacrimal gland dysfunc-
ion has been long term), they can improve overall
ymptoms of ocular GVHD.
If possible, an ophthalmologist who is knowledge-
ble about HCT and GVHD should be involved to
oordinate care in a multidisciplinary fashion. Ancil-
ary and supportive care for the eye focuses on increas-
ng ocular surface moisture (by lubrication and de-
reasing tear evaporation and tear drainage from the
urface of the eye) and on decreasing ocular surface
nﬂammation.
ubrication
For lubrication, the range of adjunctive measures
ncludes the use of preservative-free artiﬁcial tears to
oat the ocular surface, thereby minimizing superﬁcial
unctuate keratopathy (dry spots on the cornea), de-
reasing ocular symptoms, and improving quality of
ision. Because patients may tolerate certain formula-
ions better than others, they should be encouraged to
est different brands to identify one that provides the
ost beneﬁt.
For patients who may require application of arti-
cial tears more than once every hour, slowly dissolv-
ng 5-mg pellets of hydroxypropyl methylcellulose
ay provide more convenience [30]. Lacrisert is avail-
ble by prescription and is inserted once or twice daily
nto the inferior cul-de-sac of the eye but may produce
constant foreign body sensation. Oral medications
ay be used to increase lubrication by stimulating
queous tear ﬂow with selective muscarinic agonists
uch as cevimeline or pilocarpine [31]. These have
een shown to improve sicca symptoms in patients
ith Sjögren syndrome, but drug interactions and
oxicities must be reviewed, because contraindications
nclude glaucoma, heart disease, and asthma.
ontrol of Evaporation
To decrease evaporation, patients should be en-
ouraged to use warm compresses and lid care to
aximize the output of the meibomian glands that
roduce the outer oil layer of the tear ﬁlm, which
rotects against evaporation. Avoidance of low humid-
ty and use of eye protection (eg, moisture chamber
oggles) may also help to decrease evaporation [32].
oxycycline can be used to treat rosacea blepharitis/
eibomitis, thereby decreasing inﬂammation on theids and establishing an optimal oil layer to decrease m
82vaporation [33]. For refractory cases, surgery to de-
rease the exposed surface area (tarsorrhaphy) may be
ecessary [34]. Scleral lenses may also be beneﬁcial in
evere cases, but this treatment is available in only a
imited number of centers [35].
ontrol of Drainage
To decrease drainage from the surface of the eye,
emporary or permanent occlusion of the tear-duct
uncta may provide additional beneﬁt for patients
ith severe ocular sicca syndrome (5 mm tear wet-
ing) [36-38]. Permanent punctal occlusion (by ther-
al cauterization) may be necessary because the sili-
one plugs used for temporary occlusion fall out
epeatedly. Repeated thermal cautery may be needed
f puncta reopen.
ecreasing Ocular Surface Inflammation
To decrease ocular surface inﬂammation, judi-
ious use of topical steroids may be necessary. In
eneral, this type of treatment should be reserved for
he control of ocular GVHD exacerbation when sys-
emic immunosuppression is being tapered [39]. Top-
cal steroids may also beneﬁt patients with cicatricial
onjunctivitis [40]. Pulsed topical steroids should be
arefully supervised by an ophthalmologist, because
teroid-related complications include increased in-
raocular pressure, cataract formation, and silent in-
ectious keratitis. Topical cyclosporine can be pre-
cribed to control immune responses at the ocular
urface [41]. The beneﬁt of topical cyclosporine on
ear function in patients with GVHD has not been
ully elucidated, but this type of treatment increases
chirmer scores and decreases surface apoptosis in
atients with other dry eye conditions. Ocular surface
nﬂammation may also be decreased with autologous
erum, but this treatment is available in only a limited
umber of centers [42,43].
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
ULVA AND VAGINAL MUCOSA
See Table 6. Chronic GVHD involving the vulva
r vagina has been reported in approximately 3% of
one marrow recipients and 15% of peripheral blood
ecipients [44]. The diagnosis of vulvovaginal GVHD
elies on symptoms and physical ﬁndings. Histologic
onﬁrmation is strongly recommended in the absence
f diagnostic manifestations of chronic GVHD in
ther organs. Estrogen deﬁciency and infections (hu-
an papilloma virus, HSV, yeast, bacteria, or other
ecognized gynecologic pathogens) must be ruled out
t the time of initial diagnosis and periodically during
anagement of vulvar or vaginal GVHD.
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Ancillary Therapy and Supportive Care in Chronic GVHD
BChronic GVHD of the vulva and vagina presents
ith abnormalities of the mucosa or manifestations of
clerotic changes. Symptoms may include dysuria,
ryness, tenderness to touch, and dyspareunia. Mild
hronic GVHD of the vulva or vagina may occasion-
lly be asymptomatic and detected only by examina-
ion. Physical ﬁndings include erythematous patches
mucositis), retiform leukokeratosis (lichen planus-like
esions), vestibular tenderness, and, less often, excori-
tions and ulcers. Eventually, sclerosis of vulvar and
aginal tissues can lead to architectural changes such
s agglutination of the clitoral hood, narrowing of the
ntroitus, and shortening of the vaginal canal. Al-
hough most patients with vulvar or vaginal GVHD
ave involvement of the mouth or other sites, vulvo-
aginal manifestations may sometimes be the only sign
f chronic GVHD [45,46].
Symptomatic patients should be evaluated and fol-
owed by a gynecologist with experience in GVHD
nd, if not available, by practitioners with experience
n lichen planus of the genitalia.
eneral Hygiene
Irrespective of the underlying cause, the following
ygiene measures are recommended for the preven-
ion or alleviation of vulvar or vaginal symptoms.
echanical and chemical irritants should be avoided.
he genital area is best cleaned with warm water
ather than with soap or feminine wash products. The
rea may be air-dried and patients should be coun-
eled to wipe in a front-to-back direction. A small
mount of emollients or lanolin cream applied to the
xternal genitalia and not into the vagina may provide
elief from itching and irritation, provided that abnor-
al discharge (infection) is not also present. Replens
able 6. Ancillary Therapy and Supportive Care Recommendations for
Type of Inter
ulvar discomfort
Avoid mechanical and chemical irritants (eg, soap and feminine
Clean genital area with warm water, allow air circulation, and
Sparing use of simple emollients to vulva (not vagina)
Water-based lubricants
ulvovaginal symptoms and low estrogen status
Topical estrogen with/without dilator (dilator necessary only fo
opical therapy for vulvovaginal GVHD
High and ultrahigh potency corticosteroids
Clobetasol gel 0.05% (vagina)
Betamethasone dipropionate augmented gel (vagina) or oint
Tacrolimus ointment 0.1% (vulva)
urgical therapy
Surgical lysis with or without vaginal reconstruction followed b
of extensive synechiae and complete obliteration of the va
ediatric considerations
Vulvar or vaginal GVHD needs to be considered as soon as phy
pubarche; vulvovaginal GVHD has been observed infreque
Evaluation by an adolescent gynecologic practitioner is recommr other bacteriostatic gels may be used in the vagina a
B & M Tor comfort. Replens adheres to the vaginal wall and is
ntended to have a longer lasting effect than bacteri-
static water-soluble gels.
ymptomatic Low Estrogen States
If vulvovaginal symptoms and signs are accompa-
ied by low estradiol levels, topical estrogen therapy
ith or without the use of a vaginal dilator should
e initiated unless there are absolute contraindica-
ions such as increased risk of breast cancer or
ardiovascular events. Symptoms caused by gonadal
ailure generally dissipate during treatment with top-
cal estrogen. Although there is anecdotal evidence
hat estrogen replacement (systemic or topical) is an
ffective adjunctive therapy for vulvar or vaginal
VHD, prospective controlled studies are needed.
ulvovaginal GVHD
When the vulvovaginal region represents the only
linical manifestation of chronic GVHD activity, top-
cal immunosuppressive agents may constitute an ad-
quate primary therapy for controlling mild clinical
anifestations. Application of ultrahigh potency cor-
icosteroid is the mainstay of therapy, although topical
alcineurin ointments have also been used in patients
ith chronic GVHD and in other patients with erosive
ulvovaginal lichen planus disease [47-49]. Patients may
evelop candidiasis or recurrence of HSV or human
apilloma virus during immunosuppressive therapy and
ust be counseled to monitor for symptoms.
Systemic immunosuppression should be used in
atients at high risk of nonrelapse mortality (throm-
ocytopenia or requirement for systemic steroids at
ime of diagnosis). Systemic immunosuppressive ther-
and Vaginal GVHD
Rating
products) BIII
ont to back BIII
BIII
BIII
al symptoms) BIII
BIIb
vulva) BIII
BIIb
of dilator therapy may be necessary for treatment
anal BIII
evelopment has progressed beyond thelarche and into
prepubertal girls
when a diagnosis of vulvovaginal GVHD is being consideredVulvar
vention
wash
wipe fr
r vagin
ment (
y 6 mo
ginal c
sical d
ntly inpy is also indicated for vulvovaginal GVHD that
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3rogresses or fails to improve after treatment with
ocal measures. Increased systemic immunosuppres-
ive therapy or addition of local therapy is indicated if
ulvovaginal GVHD develops during systemic immu-
osuppressive treatment.
Sclerotic features of vaginal GVHD should be
reated aggressively with topical corticosteroids and
ilators. Surgical lysis with or without vaginal recon-
truction may be necessary for patients with extensive
ynechiae and complete obliteration of the vagina ca-
al. Subsequent topical treatment with calcineurin in-
ibitors has been used successfully in some cases.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
ASTROINTESTINAL TRACT AND LIVER
See Table 7. Gastrointestinal symptoms occur fre-
uently in patients with chronic GVHD. Dysphagia,
dynophagia, heartburn, anorexia, nausea, vomiting,
bdominal pain, cramping, diarrhea, weight loss, and
alnutrition may occur. It is usually unclear whether
hese symptoms are directly related to chronic GVHD,
cute GVHD, or another etiology, which makes it im-
ortant to conﬁrm the diagnosis of chronic GVHD
efore beginning treatment [50,51].
dynophagia and Dysphagia
Lubrication can ease discomfort due to xerosto-
ia. Other possible causes of odynophagia or dyspha-
ia include esophageal webs, rings, strictures, dysmo-
ility, or nonchronic GVHD diagnoses such as pill
sophagitis, radiation esophagitis, and ﬁbrosis. Endos-
opy is usually needed to exclude or conﬁrm these
iagnoses. Esophageal dilation may be helpful in pa-
ients with documented webs or strictures, but this
rocedure can cause perforation and should be per-
ormed by an experienced gastroenterologist.
iarrhea
Patients who present with diarrhea should have a
tandard evaluation including cultures, Clostridium dif-
cile toxin screen, cytomegalovirus (CMV) cultures,
ndoscopy (because CMV can cause colitis without
ntigenemia), and consideration of an alternative di-
able 7. Ancillary Therapy and Supportive Care Recommendations
or Gastrointestinal/Liver GVHD
Type of Intervention Rating
sophageal dilation for webs or stricture BIII
ietary modifications BIII
ancreatic enzyme replacement BIIa
rsodeoxycholic acid BIIa
actase tablets or lactase-containing dairy products BIII
ediatric considerationst
No substantive differences
84gnosis such as enzyme deﬁciency, bacterial over-
rowth, and medication side effects. A careful history
ay suggest secondary intestinal disaccharidase deﬁ-
iency, lactose intolerance, or pancreatic insufﬁciency.
ancreatic enzyme supplementation may be helpful in
atients with diarrhea and malabsorption. Antibiotic-
elated suppression or overgrowth of intestinal ﬂora
ay cause diarrhea. Certain medications such as mag-
esium oxide and mycophenolate mofetil may also
ause diarrhea. The use of magnesium with protein
ay decrease the risk of diarrhea, because the mineral
s bound to a soy protein, thereby eliminating the
axative effects that occur frequently with the use of
ther magnesium supplements.
bnormal Liver Function Tests
Imaging studies should be obtained if there is
uspicion of gallbladder disease or to exclude liver
bscess, inﬁltration, or other morphologic abnormal-
ty. If iron overload could be contributing to liver
unction abnormalities, additional radiographic and
aboratory studies should be performed. Use of ur-
odeoxycholic acid can help to improve biochemical
bnormalities and perhaps pruritus in some patients
ith hepatic chronic GVHD. Liver transplantation
as been used in a small number of patients with
dvanced liver chronic GVHD, but this procedure is
ot a viable treatment option in most patients [52].
eight Loss
Weight loss in patients with extensive chronic
VHD may also be caused by increased action of
lucagon and norepinephrine, resulting in an increase
n resting energy expenditure and alterations in fat and
arbohydrate oxidation rates [53]. Nutritional support
s very important because 40% of patients with
hronic GVHD are malnourished [50]. The input of a
utritionist can be very helpful in addressing weight
oss, because some patients will need total parenteral
utrition or tube feedings. A multidisciplinary team
gastroenterologist, nutritionist, oncologist, etc) may
elp to maximize the beneﬁts of therapy.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
UNG
See Table 8. The currently recognized noninfec-
ious pulmonary manifestations in patients with
hronic GVHD are HCT-related airﬂow decline and
ronchiolitis obliterans, with the latter representing a
evere form of airﬂow obstruction that is the only
iagnostic manifestation of pulmonary chronic
VHD [54]. Chronic GVHD of the lung can cause
yspnea, wheezing, coughing, air trapping, bronchiec-
asis, pneumothorax, pneumomediastinum, subcutane-
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Bus emphysema, microbial colonization or infection, and
bstructive or restrictive changes on pulmonary function
ests (PFTs). Silent pulmonary aspiration disease must
e considered in patients with chronic GVHD and
irﬂow limitation, especially in those who have
hronic postnasal drip, recurrent sinus infections, or
astroesophageal reﬂux disease [54,55].
Bronchodilators, inhaled corticosteroids [56], and
ulmonary rehabilitation programs may provide ben-
ﬁt for patients with pulmonary chronic GVHD. Pro-
hylactic immunoglobulin infusions do not prevent
ronchiolitis obliterans, and their use is not recom-
ended for this purpose [57]. If the need for supple-
ental oxygen is documented (saturation of oxyhemo-
lobin [SpO2] 87% while breathing room air), then
he amount of oxygen supplementation should be ti-
Screening PFTs 
every 3 months 
during first year
Significant
LF decline
Rule out respiratory 
infection (imaging 
and appropirate
procedure)
No inf
Yes infection
Treat and repeat 
evaluation with PFT in 
one month
No LF 
decline
Yes LF 
decline
No LF 
decline
PFTs every 
6 months 
during 2nd 
year, then 
yearly
igure 1. Possible algorithm for pulmonary monitoring after HC
bliterans syndrome; BOOP, bronchiolitis obliterans with organiz
able 8. Ancillary Therapy and Supportive Care Recommendations
or Lung GVHD
Type of Intervention Rating
nhaled corticosteroids and bronchodilators CIb
rophylactic intravenous immunoglobulin DIa
ulmonary rehabilitation CIII
upplementary oxygen AIII
ediatric considerations
Formal spirometry, lung volumes, and diffusing capacity are
not measurable in children <7 y of age, but negative
plethysmography is an option
Actual measured pulmonary function test values must be
carefully considered in pediatric patients because predicted
normal values vary with age, weight, and height; therefore,
percent predicted values might spuriously show serial
decreases over time without substantive decreases in
absolute valuesesolution; ICS, inhaled corticosteroids; LF, lung function; PFTs, pulmon
B & M Trated with the use a 6-minute walk test. Standard
-minute walk protocols should be conducted accord-
ng to guidelines of the American Thoracic Society
58]. Interventions such as inhaled cyclosporine, am-
hotericin, or tobramycin, rotating empiric antibiotics
ioneered in lung transplantation, and management of
ystic ﬁbrosis have not been rigorously tested in pa-
ients with chronic GVHD.
Because patients may have subclinical changes in
ulmonary function before a diagnosis of chronic
VHD, some experts have advocated the routine use
f PFTs to monitor for changes [54,59,60]. No studies
ave been conducted to determine the optimal inter-
als for monitoring PFTs after HCT. Recent studies
ave indicated that decreased lung function during the
rst year after HCT is signiﬁcantly associated with a
igher mortality risk [54]. In addition, changes in lung
unction at 100 days after HCT do not reﬂect the
hanges that may occur between day 100 and 1 year,
hen immunosuppressive therapy is often weaned and
ulmonary complications such as airﬂow obstruction,
ronchiolitis obliterans, and cryptogenic organizing
neumonia (also known as bronchiolitis obliterans
ith organizing pneumonia) are most likely to occur
55,61]. Studies have not been done to assess the role
f bronchoscopy or chest imaging in monitoring for
ulmonary complications after HCT [62].
Figure 1 presents 1 possible algorithm for pulmo-
ary monitoring and intervention after HCT. Full
FTs, which include spirometry, lung volumes, and
iffusing capacity of the lung for carbon monoxide
DLCO) are obtained before HCT and at 1 year after-
ard. Screening with spirometry and DLCO measure-
• Full GVHD evaluation
• Standard vs HR CT (R/O AFO vs
BOS vs BOOP), Bx if ? BOOP
• Check BD response
BOS/BOOP
• Start 
1mg/kg/d 
corticosteroid
• ICS if +BD
• Monthly 
PFTs
• CT q2weeks 
if BOOP
AFO
• ICS if +BD
• Monthly 
PFTs for 3 
months
le
Progressive
Stable
Wean steroids 
over 6 months
Adjust 
immunosuppression 
Monthly PFTs
O, airﬂow obstruction; BD, bronchodilators; BOS, bronchiolitis
eumonia; Bx, biopsy; CT, computed tomography scan; HR, highection
Stab
T. AF
ing pnary function tests; R/O, rule out.
385
m
f
c
t
t
b
T
s
[
i
[
c
L
y
w
H
d
o
m
i
u
n
f
w
T
G
m
s
o
[
h
i
a
N
s
m
m
s
c
t
c
N
p
c
m
m
t
G
m
p
t
n
p
[
p
n
a
M
w
h
o
p
t
c
e
r
M
i
T
T
f
G
I
P
*
T
f
N
N
P
*
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3ents alone can be used more frequently. If the lung
unction staging index[3] increases by 1 category in
omparison with the previous study, it is appropriate
o perform a full PFT followed by appropriate addi-
ional studies. All pulmonary function testing should
e performed according to criteria of the American
horacic Society [63] and interpretation of results
hould be conducted as summarized by Chien et al
60]. All reference values should be calculated accord-
ng to the equations of Crapo et al [64] and Hsu et al
65] for adults and children. The DLCO should be
orrected for hemoglobin but not for alveolar volume.
ung volumes should be measured with body pleth-
smography and not with a gas-based method.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
EMATOPOIETIC SYSTEM
See Table 9. Cytopenias may be caused by stromal
amage, graft failure, drug toxicity, infection, relapse
f underlying disease, CMV infection, hemolysis, ane-
ia of chronic disease, and autoimmune processes,
ncluding GVHD [66-69]. Intravenous immunoglob-
lin may be effective in certain cytopenias that have
ot improved after steroid treatment [67,69]. Growth
actor use has not been formally evaluated in patients
ith chronic GVHD and persistent cytopenias.
hrombocytopenia at the time of diagnosis of chronic
VHD is associated with poor prognosis [51,70] but
ay also be caused by autoantibodies that would re-
pond to treatment with steroids or rituximab. Eosin-
philia can occur with acute or chronic GVHD
71,72]. In patients with chronic GVHD, eosinophilia
as been associated with increased serum levels of
nterleukin 5 [73] and can herald or represent disease
ctivity [74].
EUROLOGIC SYSTEM
See Table 10. Chronic GVHD of the nervous
ystem is rare but can present as polyneuropathy,
yositis, and myasthenia [75]. Symptoms may include
uscle weakness and wasting, pain, burning, dysesthe-
ias, and paresthesias. Less clearly associated with
hronic GVHD are central nervous system manifes-
able 9. Ancillary Therapy and Supportive Care Recommendations
or Hematopoietic GVHD*
Type of Intervention Rating
rowth factors (G-CSF, GM-CSF, erythropoietin) CIII
mmunoglobulin for cytopenias CIII
ediatric considerations
No substantive differences
G-CSF indicates granulocyte colony-stimulating factor; GM-CSF,
egranulocyte-macrophage colony-stimulating factor.
86ations such as cerebral angiitis and vasculitis or en-
ephalitis-like disease [76,77].
europathy and Myopathy
Painful neuropathy and myopathy can occur in
atients with chronic GVHD [75]. Consideration of
hronic inﬂammatory demyelinating polyneuropathy
ay require cerebrospinal ﬂuid examination, electro-
yelographic studies, and sural nerve biopsy if symp-
oms present without other evidence of chronic
VHD [75,78]. Neuropathic pain can occur in a der-
atomal distribution in the absence of rash during the
rodromal phase of varicella zoster virus (VZV) reac-
ivation. Speciﬁc interventions for painful peripheral
europathies may include the use of tricyclic antide-
ressants [79], selective serotonin reuptake inhibitors
80], and anticonvulsants [81]. Narcotic analgesics are
oorly effective as a solitary approach for relieving
europathic pain, but they may provide some relief
nd can be an important adjunct to treatment [82].
edications may need to be titrated up every 1-2
eeks until symptoms are adequately controlled. Re-
abilitation medicine consultation with physical and
ccupational therapists should be considered for all
atients who have a decreased ability to perform ac-
ivities of daily living or impaired quality of life be-
ause of pain or muscle weakness. Physical therapy
valuation may be needed every 1-3 months to assess
esponse of muscle weakness and range of motion.
yasthenia Gravis and Polymyositis
Myasthenia gravis may occur in patients when
mmunosuppressive medications are being tapered.
he diagnosis is suggested by the syndrome of ptosis,
able 10. Ancillary Therapy and Supportive Care Recommendations
or Neurologic Syndromes of GVHD*
Type of Intervention Rating
europathies
Tricyclic antidepressants BIIb
SSRIs CIIb
Anticonvulsants BIb
europathies/myopathies/CNS disease
Rehabilitation medicine (PT/OT) CIII
Plasmapheresis for TTP BIIb
IVIg BIIb
ediatric considerations
Drugs of the SSRI antidepressant class should generally be
used under expert supervision because of the increased risk
of suicidal tendencies associated with their use in children
Gabapentin may be used with success for treating extremity
dysesthesias or muscle cramps
SSRIs indicates selective serotonin reuptake inhibitors; PT/OT, phys-
ical therapy/occupational therapy; TTP, thrombotic thrombocy-
topenic purpura; IVIg, intravenous immunoglobulin.xtraocular muscle weakness, and proximal limb and
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Bacial weakness in the presence of antiacetylcholine
eceptor antibodies [83].
Polymyositis can present with proximal muscle
eakness that is often painful and associated with an
ncreased serum concentration of creatinine phos-
hokinase and aldolase [84]. Isolated polymyositis as
he sole manifestation of chronic GVHD occurs
arely, and muscle biopsy may be required to establish
he diagnosis [85,86].
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
MMUNOLOGIC AND INFECTIOUS DISEASES
See Table 11. Infection is often the cause or a
ontributing factor when patients with chronic
VHD die. The immune defect in chronic GVHD is
road, encompassing macrophage function, antibody
roduction, and T-cell function. Prevention, early diag-
osis, and prompt treatment of infections are essential to
he supportive care of patients with chronic GVHD.
ost recommendations, however, are based on expert
pinion and not on controlled trials [59,87-89]. Rec-
mmendations supported by evidence are typically
ased on results from studies with patients who had
onditions other than chronic GVHD. Comprehen-
ive guidelines for the prevention of opportunistic
nfections after HCT have been published in col-
aboration by the Center for Disease Control and
revention, the Infectious Disease Society of Amer-
able 11. Ancillary Therapy and Supportive Care Recommendations fo
Interventions
ntibacterial prophylaxis
Antibiotic prophylaxis for encapsulated organisms
Pneumococcal vaccine
Hib vaccine
IVIg routinely following allogeneic HCT
IVIg in patients with chronic GVHD, hypogammaglobulinemia
infections
Antibiotic prophylaxis before dental extractions and other inva
ntifungal prophylaxis
Prophylaxis for Candida infection during chronic GVHD
Prophylaxis with agents with activity against mould during chro
Pneumocystis prophylaxis
ntiviral prophylaxis
HSV prophylaxis
VZV prophylaxis
Influenza vaccination
Early empirical treatment with oseltamivir during influenza ou
ediatric considerations
Children undergoing HCT have frequently missed routine child
patient-specific vaccination is indicated
Heptavalent-conjugated pneumococcal vaccine is recommende
recommended that children 2-5 y of age receive 1 dose of th
heptavalent-conjugated vaccine
Hib indicates Haemophilus inﬂuenzae type b conjugate, IVIg, intrav
virus.
B & M Tca, and the American Society of Blood and Marrow
ransplantation [90].
ntibacterial Prophylaxis
All patients with chronic GVHD are considered at
isk for infection with encapsulated bacteria, in par-
icular Streptococcus pneumoniae, but also Haemophilus
nﬂuenzae, and Neisseria meningitides. Prophylactic an-
ibiotics should be given to all patients with chronic
VHD as long as systemic immunosuppressive treat-
ent is being administered [91,92]. Penicillin V K is
he prophylactic agent of choice when the frequency
f penicillin-resistant S pneumoniae is low. Alternatives
nclude azithromycin or other macrolides and newer
eneration quinolones, although drug interactions can
ause problems. Daily use of trimethoprim-sulfame-
hoxazole has also been used for this indication, but its
fﬁcacy has not been demonstrated.
Antibiotic prophylaxis before dental extractions
nd other invasive procedures in patients with chronic
VHD has not been studied, and consensus on this
ubject has not been reached [59].
accinations
Although no studies have evaluated the degree of
rotection provided by pneumococcal (polyvalent
olysaccharide or heptavalent), H inﬂuenzae type b
onjugate, or inﬂuenza vaccination in patients with
hronic GVHD, most experts advocate their use be-
ause the risk of adverse outcomes with vaccination is
nologic and Infectious Consequences of GVHD*
Grade
BIIb
BIIb
BIIb
D
peated sinopulmonary
CIII
ocedures CIII
CIII
HD CIII
AIb
D
CIa
BIII
s CIII
mmunizations; review of immunization history and
and 14 mo after HCT for patients <5 y of age; it is also
alent pneumococcal vaccine 2 mo after the last dose of the
mmunoglobulin; HSV, herpes simplex virus; VZV, varicella zosterr Immu
and re
sive pr
nic GV
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3ow [93-95]. No live viruses, including the new live
ttenuated inﬂuenza vaccine and measles-mumps-
ubella vaccine, should be given. Household contacts
hould not be given oral polio vaccine.
ntravenous Immunoglobulin
Universal administration of intravenous immuno-
lobulin (IVIg) after HCT has not been shown to
onfer clinical beneﬁt and should be avoided [96,97].
n patients with hypogammaglobulinemia caused by
ther disorders, administration of IVIg to maintain
gG levels 400 mg/dL has been associated with a
ecreased incidence of severe bacterial infections [98-
00]. IVIg may be considered for patients 90 days
fter HCT who have recurrent sinopulmonary infec-
ions and serum IgG levels 400 mg/dL. Some ex-
erts recommend monitoring IgG levels and admin-
stering IVIg routinely in chronic GVHD, but there
re no data demonstrating that this approach improves
utcomes.
ntifungal Prophylaxis
There is no evidence to support the use of anti-
ungal prophylaxis 75 days after HCT. However,
nvasive mold infections are a signiﬁcant concern in
atients who receive immunosuppressive treatment
or chronic GVHD. Some centers prescribe prophy-
actic mold-active agents for patients with chronic
VHD, but this approach remains investigational be-
ause the beneﬁts and risks are unknown [101].
neumocystis Prophylaxis
Pneumocystis pneumonia 6 months after HCT
s strongly associated with chronic GVHD. All pa-
ients who receive immunosuppression after alloge-
eic HCT should receive Pneumocystis prophylaxis
102-104]. It is unknown how long prophylaxis
hould be continued after stopping immunosup-
ression, and practices vary widely across centers.
gents used for Pneumocystis prophylaxis include
rimethoprim-sulfamethoxazole, pentamidine, dap-
one, and atovaquone. Trimethoprim-sulfamethox-
zole also provides prophylaxis against toxoplasmo-
is and nocardia.
ntiviral Prophylaxis
Approximately 30-60% of patients develop an ep-
sode of zoster during the ﬁrst year after discontinuing
ost-transplant prophylaxis [105]. Some experts use
ong-term antiviral prophylaxis to prevent recurrent
SV and VZV infection among HCT recipients with
evere, long-term immunodeﬁciency [106-108], but
urrent evidence does not support routine administra-
ion of antiviral prophylaxis for HSV in patients with
hronic GVHD. If VZV-seronegative patients with
hronic GVHD are exposed to varicella (primary or r
88ostvaccination illness), VZV Ig should be given
ithin 96 hours.
CMV disease after day 100 has become more com-
on. The best strategy to monitor and treat CMV
fter day 100 has not been deﬁned. Patients with
ctive GVHD [109], a history of CMV reactivation
uring the ﬁrst 3 months, and lymphopenia are at
igher risk of CMV reactivation and death. Some
enters continue to monitor for CMV infection after
ay 100 by pp65 antigenemia or polymerase chain
eaction (PCR) tests, followed by preemptive therapy,
ased on the individual risk as determined by donor
nd recipient serology, as follows:
CMV seronegative (donor and recipient): No
prophylaxis, no antigenemia (or PCR) checks
CMV seropositive (donor or recipient):
● No history of CMV infection: CMV surveil-
lance testing (antigenemia or PCR) every 1-4
weeks
● History of CMV infection or disease: Weekly
CMV surveillance testing (antigenemia or
PCR) and preemptive treatment as during the
ﬁrst 100 days
Some investigators have advocated early empirical
reatment of inﬂuenza with neuraminidase inhibitors
uring inﬂuenza outbreaks by using prediction rules
ased on symptoms and signs [110,111], although
here is no evidence to support this practice.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
USCULOSKELETAL
See Tables 12 and 13. Musculoskeletal complica-
ions after HCT are caused by chronic GVHD and its
reatment with corticosteroids. The most frequent
roblems include fasciitis, sclerotic contractures and
imitation in the range of motion, steroid-induced
yopathy, and osteoporosis. The topic of fasciitis and
clerotic changes has been partly covered under Skin
nd Appendages.
This section will focus on rehabilitation for disor-
ers of mobility associated with fasciitis, contractures,
nd steroid myopathy and on prevention and manage-
ent of osteopenia/osteoporosis.
ehabilitation in Patients with Chronic GVHD
Impairments such as joint contractures, limb
welling, and muscle atrophy and weakness are often
een in chronic GVHD. Functional loss associated
ith these impairments includes decreased mobility,
atigue, and a decreased ability to perform activities of
aily living or work-related activities [112,113]. As-
essment of the patient depends on comprehensive
euromusculoskeletal examination testing strength,
ange of motion of affected joints, limb girth, pain
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Bobility, stamina and activities of daily living, and
ubjective measurements of disability. Whenever pos-
ible, treatment should be aimed at early intervention
nd prevention of severe joint contractures and decon-
itioning. Restoration of range of motion, strength,
obility, and relief of pain are some of the essential
ehabilitation goals [114-116]. Options include ag-
ressive physical therapy or a home-based program.
hese considerations emphasize the central role of
hysical and occupational therapies in the multidisci-
linary team caring for patients with chronic GVHD.
revention and Management of Osteoporosis
Bone mineral metabolism is disturbed after allo-
eneic HCT, even at 6 years [117-120]. The abnor-
alities described after HCT include increased bone
esorption and decreased bone formation, with con-
equent osteopenia and, less frequently, osteoporosis.
fter HCT, bone mineral density (BMD) of the fem-
ral neck may be more affected than the vertebrae,
nlike postmenopausal osteoporosis [121-123]. The
ecommendations for prevention and treatment of os-
eoporosis in patients with chronic GVHD are based
n experience with osteoporosis in other diseases such
s breast and prostate cancers and on expert consen-
us.
In patients with chronic GVHD, a baseline cal-
ium (total and ionized) and vitamin D levels should
e tested. These tests should be repeated at least
nnually when normal or as clinically indicated when
bnormal or predicted to become abnormal. The con-
ideration of secondary causes of osteoporosis at this
tage is also critical. Referral to an endocrinologist is
arranted whenever an endocrine, secondary cause
f osteoporosis such as hyperparathyroidism is sus-
ected [119].
BMD measurement by dual-energy x-ray absorp-
able 12. Ancillary Therapy and Supportive Care Recommendations
or Fasciitis, Contractures, and Steroid Myopathy
Type of Intervention Rating
asciitis/contractures
Refer to physical therapy for quantitative range
of motion measurements, to provide the
patient with stretching exercises, and to
monitor progress AIII
Evaluation of range of motion at each clinic visit AIII
Daily stretching exercises at home AIII
Physical therapy stretching 2-3 times a week
(severe impairment) AIII
Surgical release DIII
teroid myopathy and deconditioning
Strengthening: isometric, isotonic, isokinetic
exercises AII
Decreased stamina: aerobic exercise—should be
progressive with increase in duration and
resistance to increase heart rate AIIIiometric scans is recommended in patients with
B & M Thronic GVHD. The resulting T score indicates the
umber of SDs above or below the average BMD for
ealthy white women. T scores 1.5 indicate os-
eopenia and those 2.5 indicate osteoporosis.
MD studies should be repeated yearly for the ﬁrst 3
ears after HCT and, if BMD is stable, every 2-3 years
hereafter [119].
Management consists of calcium and vitamin D
upplementation and antiresorptive therapy.
Calcium and vitamin D. Replacement is justiﬁed in
eﬁcient states or when patients are postmenopausal
r at high risk of developing deﬁciency [124,125] but
s not adequate in patients with osteoporosis [126].
Antiresorptive therapy. In patients in whom steroid
herapy is expected to last 3 months, a BMD study
hould be performed and antiresorptive therapy
hould be started regardless of the results. Preferred
ntiresorptive therapy includes hormonal replacement
r bisphosphonates [126-128]. Secondary options in-
lude raloxifene or calcitonin [126].
In patients who are not taking steroids for ex-
ended periods, recommendations are based on BMD
scores. Antiresorptive therapy is indicated if the
MD T score is 1.5. Patients with T scores
1.5 should be followed closely with BMD studies
early for 3 years and, if stable, every 2-3 years
hereafter.
For speciﬁc dispensing information, please see
ww.asbmt.org/GvHDForms.
SYCHOSOCIAL
See Table 14. Studies of late effects in patients
fter allogeneic HCT have suggested that chronic
VHD produces deleterious consequences for multi-
able 13. Recommendations for Prevention and Management
f Osteoporosis
Recommendation Rating
alcium and vitamin D replacement in deficient
states, postmenopausal women, and high
risk of deficiency AIb
ntiresorptive therapy when prolonged
corticosteroid administration (>3 mo) AIIb
ntiresorptive therapy
In patients off steroids and T score <1.5 AIIb
In patients with higher T scores DIII
ediatric considerations
The definition of decreased bone mineral density in children
uses age- and sex-normalized SD scores (Z scores) rather
than T scores. Osteopenia is a Z score <1.5 and
osteoporosis is a Z score <2.5. The incorrect application
of T scores to children may lead to inappropriate
misdiagnosis and overtreatment
The published use of bisphosphonates in children is limited,
and most experience is with pamidronate
Use of oral bisphosphonates is even less studied than the use
of parenteral formulations
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3imensional functioning and quality of life [92,129-
32]. The literature has shown that patients with
hronic GVHD report signiﬁcantly more fatigue,
ain, bowel changes, and dyspareunia than do those
ithout chronic GVHD [92,132]. Physical, sexual,
nd social functioning is also lower in patients with
hronic GVHD [92,132], and patients with more se-
ere chronic GVHD have impaired physical and psy-
hosocial recovery at 1 year after HCT [131] and long
erm [130] (Table 14). Chiodi et al [129] reported that
hronic GVHD was the most important factor inﬂu-
ncing diminished vocation and domestic role func-
ion and that chronic GVHD negatively affected fam-
ly interactions and social activities. Although
xtensive chronic GVHD was a consistent negative
redictor of impaired quality of life, continued immu-
osuppressive therapy itself did not appear to have a
egative inﬂuence on quality of life [129].
Research has suggested that the experience of long
urvivorship after allogeneic HCT and its associated
ymptoms and late term effects, including chronic
VHD, can cause negative changes in self-concept
133], mood disturbance [131,134,135] including de-
ression [131,134,136] and anxiety [131,137], psycho-
ocial distress [134,138], and diminished social rela-
ionships and social function [134,139,140].
Some of the more prevalent psychosocial situa-
ions associated with chronic GVHD include neuro-
ognitive impairment and mood alterations, altered
ody image, sexual dysfunction, and fatigue.
eurocognitive Functioning, Depression,
nd Anxiety
Neurocognitive performance usually decreases
hortly after HCT and recovers in most patients by 1
ear [131]. Chronic GVHD has not been associated
ith any speciﬁc intellectual function deﬁcits, but im-
unosuppressive medications have not been speciﬁ-
ally tested as risk factors in children. Thus, neuro-
sychological testing may be indicated if patients or
amilies report difﬁculty with home- or work-related
able 14. Ancillary Therapy and Supportive Care Recommendations
or Psychosocial Issues
Type of Intervention Rating
europsychological testing and rehabilitation for
long-term survivors (>1 y) when cognitive
deficits impair work or disrupt daily
activities and safety CIII
eferral to a specialist and appropriate
treatment of depression, anxiety, and pain BIII
upportive and cognitive behavioral
interventions for body image issues, sexual
functioning, and fatigue BIII
ediatric considerations
No substantive differencesognitive or motor tasks that persist for 1 year after m
90CT. Reassurance and rehabilitation approaches that
each adaptive strategies can be useful.
Depressive symptoms are more severe and longer
erm in HCT recipients who have extensive chronic
VHD [133]. Depression and other mental status
hanges should be assessed concurrently with neuro-
ognitive function, because depression or distress is
ften the source of complaints about concentration or
emory [133]. The presence of chronic GVHD does
ot alter the usual management of depression and
nxiety.
ody Image
Body image can be greatly affected by the mani-
estations and treatment of chronic GVHD. Body
mage is dynamic and affects an individual’s feelings
f body function, appearance, and sensations [141].
cross the age spectrum, patients with chronic
VHD who have changes in their body image may
xperience frustration, anger, anxiety, guilt, and de-
ression. In particular, school-age children and ado-
escents face the additional challenge of peer accep-
ance. Changes in body image signiﬁcantly affect their
bility to meet these psychosocial and developmental
eeds. In adults, role abandonment and ineffective-
ess, social isolation and loneliness, and sexual dys-
unction are also potential sequelae. Provision of psy-
hological and emotional support to patients and their
aregivers, education, cognitive-behavioral interven-
ions, and medications may be helpful if depression or
nxiety is also present.
exual Dysfunction
Sexual problems for men and women may include
atigue, loss of partnership role and independence,
nfertility, gonadal ablation, sleep dysfunction, ﬁnan-
ial concerns, and changes in body image involving
air loss, rash, sclerosis, body weight, body odors, and
owel and bladder function. Interruption of sexual
ctivity and sexual difﬁculties for prolonged periods
fter HCT are common manifestations [142]. Thera-
eutic options for sexual dysfunction usually begin
ith counseling: identifying the problems with the
ouple or individual, helping overcome anxiety, and
ddressing the concerns of patients who do not have a
artner. Speciﬁc therapies may include gradual re-
umption of sexual activities, positions, use of pillows
nd props, creating an intimate atmosphere, and set-
ing a time of day when the patient is least tired.
ouples, regardless of sexual orientation, need to
now that pleasure from touching, that does not nec-
ssarily culminate in intercourse, almost always re-
ains.
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Batigue
Fatigue is deﬁned as a persistent and subjective
ense of tiredness that interferes with usual function-
ng [143]. The biochemical, physiological, psycholog-
cal, and behavioral mechanisms of this syndrome are
oorly understood [144]. Although little is known
bout the prevalence, correlates, or predictors of fatigue
n individuals with chronic GVHD, empirical evidence
nd clinical practice support a conclusion that fatigue
emains a prevalent and distressing symptom for many
ears after allogeneic HCT [130,145,146].
Energy conservation measures (set priorities, del-
gate, pace, schedule activities at time of peak energy,
tructure daily routine), initiation of a low impact or
eated exercise program, referral to physical therapy
nd rehabilitation for exercise prescription, psychoso-
ial interventions (stress management, relaxation, cog-
itive behavioral therapy, or support group), nutrition
onsultation, management of other concurrent dis-
ressing symptoms including pain, avoidance or limi-
ation of pharmacologic agents with sedating side ef-
ects, efforts to improve sleep patterns (sleep hygiene,
ypnotics), attention-restoring therapy (eg, natural
nvironment activities), distraction (eg, music, social-
zing), and psychostimulants (eg, methylphenidate,
ntidepressants) may be helpful. The National Com-
rehensive Cancer Network has produced a consensus
ocument summarizing the available interventions for
anagement of fatigue during and after cancer treat-
ent [143].
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ppendix A. Evidence-Based Rating System for Ancillary Therapy
nd Supportive Care Guidelines in Chronic Graft-versus-Host Disease
Category Definition
trength of the recommendation
A Should always be offered.
B Should generally be offered.
C Evidence for efficacy is insufficient to support a
recommendation for or against, or evidence for
efficacy might not outweight adverse
consequences, or cost of the approach. Optional.
D Moderate evidence for lack of efficacy or for
adverse outcome supports a recommendation
against use. Should generally not be offered.
E Good evidence for lack of efficacy or for adverse
outcome supports a recommendation against
use. Should never be offered.
uality of evidence supporting the recommendation
I Evidence from >1 properly randomized, controlled
trial.
II Evidence for >1 well-designed clinical trial without
randomization, from cohort or case-controlled
analytic studies (preferable from >1 center), or
from multiple time series or dramatic results
from uncontrolled experiments.
III Evidence from opinions of respected authorities
based on clinical experience, descriptive.
ualifier for categories I and II
a Evidence derived directly from study(s) in
graft-versus-host disease.
b Evidence derived indirectly from study(s) inanalogous or other pertinent disease.
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